コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 lated health care use among individuals with advanced cancer.
2 ogical interventions for adult patients with advanced cancer.
3 temic inflammatory response in patients with advanced cancer.
4 py may be relevant in fibrotic disorders and advanced cancer.
5 ative therapeutic approach for patients with advanced cancer.
6 anscriptomic subset across distinct types of advanced cancer.
7 elationships when one of their relatives has advanced cancer.
8 arameters independent of PS in patients with advanced cancer.
9 es but also enhances coping in patients with advanced cancer.
10 sion medicine trial focused on patients with advanced cancer.
11 thnicity and rates of IPCC for patients with advanced cancer.
12 e care in the hospital for all patients with advanced cancer.
13 less optimistic message) with a patient with advanced cancer.
14 pear to suffice for a cell to evolve into an advanced cancer.
15 ntial or spiritual distress in patients with advanced cancer.
16 lized immunotherapies to treat patients with advanced cancer.
17 ressive management of pain for patients with advanced cancer.
18 RON kinase in the prevention or treatment of advanced cancer.
19 tentially curative therapy for patients with advanced cancer.
20 secondary supportive care for patients with advanced cancer.
21 d phase I/Ib clinical trial in patients with advanced cancer.
22 onizes human OX40 signaling in patients with advanced cancer.
23 D (25(OH)D) concentrations in patients with advanced cancer.
24 and treatment adherence in young adults with advanced cancer.
25 tool on CPR preferences among patients with advanced cancer.
26 paradigm shift in therapy for patients with advanced cancer.
27 tment adherence in young adult patients with advanced cancer.
28 ality of life, and survival in patients with advanced cancer.
29 nd-of-life decision making for patients with advanced cancer.
30 is the most common symptom in patients with advanced cancer.
31 Cancer-related-fatigue (CRF) is common in advanced cancer.
32 ing CRF and quality of life in patients with advanced cancer.
33 from a variety of chronic diseases including advanced cancer.
34 class of molecular agents designed to treat advanced cancer.
35 lieving refractory symptoms in patients with advanced cancer.
36 odifiable fall risk factors in patients with advanced cancer.
37 hocytes is a promising approach for treating advanced cancer.
38 reduced the rate at which women present with advanced cancer.
39 ides a hopeful new therapy for patients with advanced cancer.
40 ffering and quality of life in patients with advanced cancer.
41 ime a person is diagnosed with metastatic or advanced cancer.
42 n acceptable safety profile in patients with advanced cancer.
43 ual well-being and meaning for patients with advanced cancer.
44 n with and decision making for patients with advanced cancer.
45 e transthoracic group had significantly more advanced cancer.
46 vaccines for the treatment of patients with advanced cancer.
47 s likely to be ineffective by itself against advanced cancer.
48 t of disease that is unlikely to progress to advanced cancer.
49 therapies have shown value in the setting of advanced cancer.
50 ctual EOL care received in 325 patients with advanced cancer.
51 nous doses of rhApo2L/TRAIL in patients with advanced cancer.
52 ng these decisions on behalf of a child with advanced cancer.
53 ith communication about being diagnosed with advanced cancer.
54 terventions for presently incurable forms of advanced cancer.
55 term clinical benefits to many patients with advanced cancer.
56 vailable treatment options for patients with advanced cancer.
57 he clinical benefit of ICIs in patients with advanced cancer.
58 y of life (QOL) and mood among patients with advanced cancer.
59 in patients with delirium in the setting of advanced cancer.
60 d nilotinib with paclitaxel in patients with advanced cancer.
61 ociated with a reduction in the incidence of advanced cancer.
62 liver the standard of care for patients with advanced cancer.
63 ity of life (QOL) and mood for patients with advanced cancer.
64 nt of resistance to therapy is inevitable in advanced cancer.
65 anticancer T cell responses in patients with advanced cancers.
66 Cs, they were clonal and highly prevalent in advanced cancers.
67 al implications for therapeutic targeting of advanced cancers.
68 a successful treatment strategy for several advanced cancers.
69 losion of novel targeted immunotherapies for advanced cancers.
70 e inactivation becomes more frequent in more advanced cancers.
71 ineoplastic drug used in the clinic to treat advanced cancers.
72 ials to assess its efficacy for treatment of advanced cancers.
73 orbidity and mortality of many patients with advanced cancers.
74 f TILs and antigen receptor gene therapy for advanced cancers.
75 ic alterations from low risk to high risk to advanced cancers.
76 associated with acquired drug resistance in advanced cancers.
77 blockade to enhance TCR gene therapy against advanced cancers.
78 of class I PI3K inhibition in patients with advanced cancers.
79 eceived regulatory approval for treatment in advanced cancers.
80 increased expression in tumor cell nuclei of advanced cancers.
81 am of body weight) to patients with selected advanced cancers.
82 d death receptor-1 blockade in patients with advanced cancers.
83 odalities for the treatment of patients with advanced cancers.
84 and activation of oncogenes is essential in advanced cancers.
85 ation are associated with worse prognosis in advanced cancers.
86 ost promising approaches to immunotherapy of advanced cancers.
87 a phase 1/2 clinical trial in patients with advanced cancers.
88 GFbeta appears to promote the progression of advanced cancers.
89 s are a promising approach for patients with advanced cancers.
90 ed for a normal human cell to progress to an advanced cancer?
92 tively characterized cohort of patients with advanced cancer, 642 of 1,168 (55%) with KRAS mutations
94 allel-group, randomised trial, patients with advanced cancer, aged at least 18 years, admitted to the
95 es and in circulating ECs from patients with advanced cancers, ALK1 blockade may represent an effecti
96 er Center, Texas, enrolling 93 patients with advanced cancer and agitated delirium despite scheduled
97 que cohort of more than 10,000 patients with advanced cancer and available pathological and clinical
98 eletal-related events (SRE) in patients with advanced cancer and bone metastases (excluding breast an
99 er improves quality of life in patients with advanced cancer and does not seem to shorten survival; t
100 s the existing literature on polypharmacy in advanced cancer and end-of-life settings by reviewing ev
101 Concordance between parents of children with advanced cancer and health care providers has not been d
102 human iNKT cells were limited to therapy of advanced cancer and led to only modest activation of inn
103 ppaB signaling appears to be correlated with advanced cancer and promotes tumor metastasis by influen
104 fects of TRX518 monotherapy in patients with advanced cancer and provide mechanistic preclinical evid
105 t improves quality of life for patients with advanced cancer and reduces the risk of depression for c
106 linical course of skeletal muscle wasting in advanced cancer and the window of possible muscle anabol
108 rvention was effective to help patients with advanced cancer and their caregivers identify and bring
109 delivery of palliative care to patients with advanced cancer and their families, whether done by onco
111 letal muscle index (SMI) measurements during advanced cancer and their relationships with disease pro
113 ing syndrome that affects most patients with advanced cancers and causes severe body weight loss, wit
114 d clinical evaluation in adult patients with advanced cancers and has the potential to treat tumors r
115 markable anti-tumor effects in patients with advanced cancers and is recognized as the gold standard
116 aying treatment initiation, particularly for advanced cancers and neoadjuvant therapies, require cont
117 vention involving oncologists, patients with advanced cancer, and caregivers would promote patient-ce
118 py-related hospitalizations in patients with advanced cancer are common, distressing, and costly.
122 include high drop-out rates, consistent with advanced cancer, as well as variability across studies i
123 icacy, targeted therapies eventually fail in advanced cancers, as tumors develop resistance and relap
124 ists as therapeutic agents in the setting of advanced cancers, as well as the mechanisms through whic
125 tober 2010 and March 2013, 207 patients with advanced cancer at a National Cancer Institute cancer ce
127 st of criteria for referral of patients with advanced cancer at secondary or tertiary care hospitals
128 xpansion study of rogaratinib in adults with advanced cancers at 22 sites in Germany, Switzerland, So
129 ceptor blockade has changed the treatment of advanced cancers, at times inducing prolonged remission.
130 has been proposed as a therapeutic target in advanced cancers based on increased expression in primar
131 uideline recommending that all patients with advanced cancer be referred to palliative care providers
132 ing lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained o
133 oint blockade is revolutionizing therapy for advanced cancer, but many patients do not respond to tre
134 o produce durable responses in patients with advanced cancer, but they have only modest efficacy and
135 to PI3K/AKT/mTOR inhibitors in patients with advanced cancers, but the relevance of mutation subtype
138 regiver outcomes, use measures validated for advanced cancer caregivers, and test real-world interven
140 ectations and end-of-life care wishes in the advanced cancer context, the communication support progr
142 015, focused entirely on the question of why advanced cancer cure is so uncommon despite the extraord
145 ta were collected for adult patients with an advanced cancer diagnosis admitted to five US hospitals
148 eptomeningeal metastases, within 3 months of advanced cancer diagnosis for patients with median survi
151 ss in 104 children age 2 years or older with advanced cancer enrolled onto the Pediatric Quality of L
153 associated with caregiving for patients with advanced cancer, evaluate the evidence for pertinent int
154 hat immune effector cells from patients with advanced cancers exhibit reduced activation of IFN signa
159 with radiation therapy for men with locally advanced cancers (for whom a survival benefit was establ
166 These challenges demonstrate the need for advanced cancer imaging informatics tools that can help
167 nt-initiated palliative care consultation in advanced cancer improves quality of life in patients wit
168 ) to providers and families of children with advanced cancer improves symptom distress and health-rel
169 r 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-de
170 mbrolizumab is approved for the treatment of advanced cancer in adults; however, no information is av
171 ytes (TIL) results in complete regression of advanced cancer in some patients, but the efficacy of th
176 ace many challenges caring for patients with advanced cancer: inadequate funding; inequitable distrib
177 ed promise in the treatment of patients with advanced cancers including glioblastoma, the factors dic
178 n is a poor prognosis marker in a variety of advanced cancers, including colorectal, breast, and lung
179 s of 12 to 41% at 24 weeks) in patients with advanced cancers, including non-small-cell lung cancer,
180 -L1) have shown marked efficacy against many advanced cancers, including those that are negative for
182 Positive religious coping in patients with advanced cancer is associated with receipt of intensive
185 e of deep venous thrombosis in patients with advanced cancer is unconfirmed and it is unknown whether
187 oss of epithelial integrity is a hallmark of advanced cancer, it remains poorly understood whether ge
188 the repertoire of targetable alterations in advanced cancers, it is necessary to sequence recurrent
190 astases and vasogenic edema in patients with advanced cancer, leading to reduced morbidity and associ
194 tify the most effective drug combinations in advanced cancer models, thereby improving personalized d
197 ncer treatment in special populations (e.g., advanced cancer, non-western populations), or on broad d
199 .01), and had lower odds of an FN finding of advanced cancer (odds ratio, 0.9 [95% CI: 0.5, 1.5]).
200 erapy (odds ratio, 1.74; 95% CI, 1.48-2.03), advanced cancer (odds ratio, 2.57; 95% CI, 1.44-4.60), a
205 ch palliative care services to patients with advanced cancer on the basis of care complexity and pati
207 family of a hospitalized patient dying with advanced cancer or hematologic disease in which the limi
209 per week, children age >/= 2 years old with advanced cancer or their parent completed the computer-b
211 symptoms commonly experienced by people with advanced cancer: pain, breathlessness, nausea and vomiti
212 rmed a retrospective analysis of consecutive advanced cancer patient treated with PD-1/PD-L1 checkpoi
213 lopment of the 1F5 mAb, for which studies in advanced cancer patients have been initiated under the n
214 w board-IRB-approved retrospective review of advanced cancer patients on ICIs who received the flu va
215 lyzed the clinical and genomic data of 1,662 advanced cancer patients treated with ICI, and 5,371 non
216 We determined the HLA-I genotype of 1535 advanced cancer patients treated with immune checkpoint
217 SMI is associated with shortened survival in advanced cancer patients treated with PD1/PDL1 checkpoin
223 whether in the type of resection in locally advanced cancer plays a role in prognosis and whether TH
224 , few data for specific interventions in the advanced cancer population are available, and thus more
226 tilization, and survival in ED patients with advanced cancer randomized to ED-initiated palliative ca
228 The median survival of 212 patients with advanced cancer referred to phase I care after the initi
234 The Cancer Genome Atlas (TCGA) has greatly advanced cancer research by generating, curating and pub
235 tack mtDNA and exhibited otherwise-resistant advanced cancer sensitive to cisplatin-based chemotherap
237 Clinicians working with patients who have advanced cancer should consider IMCP as an approach to e
238 ommendations Inpatients and outpatients with advanced cancer should receive dedicated palliative care
240 at high levels of MDSCs correlated with more advanced cancer stage and with reduced survival (p = 0.0
246 This expression significantly increases at advanced cancer stages, providing an improved opportunit
247 MSCC) can be a catastrophic manifestation of advanced cancer that causes immobilizing pain and signif
248 nts with agitated delirium in the setting of advanced cancer, the addition of lorazepam to haloperido
253 aim to match patients with a broad range of advanced cancers to early phase clinical trials on the b
255 These results also show that the extent of advanced cancer traits, such as invasion, may be determi
256 th poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimuma
257 In this referral population with selected advanced cancers, universal sequencing of a broad panel
258 lliative care consultation for patients with advanced cancer vs usual care took place from June 2011
260 ms, there is support for the hypothesis that advanced cancer was associated with an acute inflammator
261 tion training and coaching for patients with advanced cancer was effective in improving patient-cente
263 t the implementation of ACP in patients with advanced cancer, we conducted a cluster-randomised trial
264 ist intervention to improve communication in advanced cancer, we conducted a post hoc analysis of the
265 rent burden of polypharmacy in patients with advanced cancer, we expect that greater attention to pol
266 prospective clinical sequencing program for advanced cancers, we enrolled 11 patients with ER-positi
267 -five young adults (age 20 to 40 years) with advanced cancer were administered measures of alliance,
270 ear after diagnosis, 71% of individuals with advanced cancer were hospitalized, 16% had three or more
272 er 2010 and March 2013, CGs of patients with advanced cancer were randomly assigned to receive three
274 Since May 2015, 1040 of these patients with advanced cancer were referred by their oncologists for g
275 ws the evidence for improved patient care in advanced cancer when patients' individual goals and pref
276 st commonly applied: soon after diagnosis of advanced cancer, when living with the disease, and at or
277 s provide substantial care for patients with advanced cancer, while suffering from hidden morbidity a
278 ted a prospective study of 932 patients with advanced cancer who experienced an unplanned hospitaliza
280 study assessed outcomes of individuals with advanced cancer who required admission to an intensive c
281 erience with 2,000 consecutive patients with advanced cancer who underwent testing on a genomic testi
283 inal cohort study of 265 adult patients with advanced cancer who visited 38 oncologists within commun
285 cluding English-speaking adult patients with advanced cancer who were able to understand the nature o
287 gn, Setting, and Participants: Patients with advanced cancer who were referred to dermatology at Yale
288 ve, longitudinal cohort of 345 patients with advanced cancer, who were enrolled between January 1, 20
294 itor SCCA1 (SERPINB3) is upregulated in many advanced cancers with poor prognosis, but there is limit
296 a phase I/II clinical trial in patients with advanced cancers without harming normal cells or tissues
298 current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biops
299 of life (QOL), and aggressive treatments in advanced cancer, yet few randomized clinical trials (RCT